During the past decade, NYU Langone Long Island Clinical Research Associates conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "NYU Langone Long Island Clinical Research Associates" are "Advanced or Metastatic Colorectal Cancer" (1 trials) and "Crohn's Disease" (1 trials). Many other conditions were trialed in "NYU Langone Long Island Clinical Research Associates" in a lesser frequency.

Most popular intervention types in "NYU Langone Long Island Clinical Research Associates" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Amivantamab" (1 trials), "Fluorouracil" (1 trials), "Guselkumab" (1 trials), "Guselkumab Dose 1" (1 trials) and "Guselkumab Dose 2" (1 trials). Other intervention names were less common.

The vast majority of trials in "NYU Langone Long Island Clinical Research Associates" are 2 trials for "All" genders.

Currently, there are NaN active trials in "NYU Langone Long Island Clinical Research Associates". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in NYU Langone Long Island Clinical Research Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in NYU Langone Long Island Clinical Research Associates, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".